Join
Live feed
·
PRReleasevia Quantisnow
Eton Pharmaceuticals Inc. logo

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

ByQuantisnow·Wall Street's wire, on your screen.
ETON· Eton Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ETON (Eton Pharmaceuticals Inc.) and more on Quantisnow.